KCM
PGNX

Kennedy Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Kennedy Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-513,375
Closed -$3.25M – 785
2016
Q3 		$3.25M Sell
513,375
-107,982
-17% -$653K 0.06% 485
2016
Q2 		$2.62M Buy
621,357
+8,196
+1% +$39.6K 0.05% 515
2016
Q1 		$2.67M Sell
613,161
-7,590
-1% -$33.8K 0.05% 528
2015
Q4 		$3.81M Sell
620,751
-2,024
-0.3% -$13.3K 0.08% 440
2015
Q3 		$3.56M Buy
622,775
+397,775
+177% +$3.05M 0.07% 452
2015
Q2 		$1.68M Buy
+225,000
New +$1.36M 0.03% 618

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kennedy Capital Management's PGNX Position: Q4 2016 in Review

Kennedy Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2016, closing a stake of 513,375 shares — an estimated $3.25M sold.

Kennedy Capital Management first reported a position in PGNX in Q2 2015 and held it in 6 quarters. The position peaked at $3.81M in Q4 2015. 126 funds tracked by Wall St. Rank hold PGNX as of Q4 2016.

  • Kennedy Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2016 after selling out during the quarter.
  • Kennedy Capital Management sold 513,375 Progenics Pharmaceuticals Inc shares in Q4 2016, an estimated $3.25M.
  • Kennedy Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q2 2015 and held it in 6 quarters.
  • Kennedy Capital Management's Progenics Pharmaceuticals Inc position peaked at $3.81M in Q4 2015.
  • 126 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2016.

Based on Kennedy Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.